Please login to the form below

Not currently logged in
Email:
Password:

romosozumab

This page shows the latest romosozumab news and features for those working in and with pharma, biotech and healthcare.

FDA rejects Amgen's osteoporosis hope romosozumab

FDA rejects Amgen's osteoporosis hope romosozumab

FDA rejects Amgen's osteoporosis hope romosozumab. Its partner UCB plans to submit the medicine for European approval later this year. ... The FDA has turned down Amgen's marketing application for osteoporosis candidate romosozumab, asking for new data

Latest news

  • CHMP recommends Merck & Co's Lantus biosimilar CHMP recommends Merck & Co's Lantus biosimilar

    competition. Furthermore, Amgen and UCB's rival osteoporosis drug romosozumab has demonstrated superior results to Forteo in phase III trials, and analysts have suggested the emerging anti-sclerostin antibody class will

  • Amgen's Kyprolis scarred by head-to-head duel with Velcade Amgen's Kyprolis scarred by head-to-head duel with Velcade

    Romosozumab filed. There was some better news for Amgen and partner UCB this week when the FDA started its review of romosozumab, their drug candidate for the treatment of osteoporosis in ... Romosozumab did well in phase III trials - cutting the risk of

  • Merck decision to drop odanacatib lifts UCB/Amgen Merck decision to drop odanacatib lifts UCB/Amgen

    Their anti-sclerostin antibody romosozumab is well ahead of other drugs in the emerging class and has been shown to be superior to Eli Lilly's big-selling osteoporosis therapy Forteo ... Deutsche Bank analysts have said they see romosozumab and

  • Amgen and UCB's romosozumab hits goals in male osteoporosis Amgen and UCB's romosozumab hits goals in male osteoporosis

    Patients in the trial were given a subcutaneous injection of romosozumab or placebo every month for a year. ... Amgen and UCB previously reported data showing romosozumab was superior to Forteo, which also requires daily dosing by injection.

  • Amgen says romosozumab on track for 2016 filing Amgen says romosozumab on track for 2016 filing

    Amgen says romosozumab on track for 2016 filing. Reports ‘ significant’ reduction of fractures in post-menopausal osteoporosis patients. ... Importantly, at 12 months the reduction was around 73 per cent, indicating that romosozumab can get to work

More from news
Approximately 6 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Investing in the future of R&D Investing in the future of R&D

    One of UCB's brightest prospects is its osteoporosis candidate romosozumab. In January phase II trial results were published that showed significant increases in low bone mineral density at both spine

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    Providing an example, he explains UCB's use of genetics in its development of romosozumab, currently in phase III investigation in partnership with Amgen for use in the treatment of ... UCB's work on romosozumab with Amgen is also an example of the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics